Exact Sciences Corp
Exact Sciences Announces Updated Financial Projections for Merger with Abbott Laboratories
Summary
Exact Sciences Corporation has announced updated financial projections for its pending merger with Abbott Laboratories. The company has amended its Definitive Proxy Statement to include additional financial analysis by Centerview Partners LLC. The analysis includes a discounted cash flow analysis, selected public company analysis, and selected precedent transactions analysis. The updated projections show estimated revenue, net income, adjusted EBITDA, and unlevered free cash flow for Exact Sciences from 2025 through 2034. The company also disclosed that the Per Share Merger Consideration of $105.00 in cash, without interest, is above the implied per share equity value range calculated by Centerview. The merger is subject to certain conditions, including regulatory approvals and the vote of Exact Sciences stockholders.
Profitelligence Alerts
Get alerts for EXAS
Be first to know when Exact Sciences Corp files with the SEC.
Filing Categories
Advertisement
About Exact Sciences Corp
Exact Sciences Corp is a prominent biomedical and biotechnology company dedicated to the development, manufacturing, and marketing of proprietary diagnostic tests. Headquartered in Madison, Wisconsin, the company is renowned for its innovative work in the early detection and prevention of colorectal cancer, primarily through its flagship product, Cologuard. This non-invasive stool-based DNA screening test is a breakthrough in cancer diagnostics, allowing for easier and earlier detection of cancerous and pre-cancerous conditions without the need for traditional invasive procedures. Exact Sciences plays a vital role in the health care and life sciences sectors, significantly impacting patient care by providing more accessible screening options. Their commitment to research and development is evident through ongoing efforts to expand their diagnostic offerings, which include tests for other critical health conditions. In the financial markets, Exact Sciences is a key player in the medical diagnostics and biotechnology industries, with substantial influence on the development of new cancer screening methodologies. The company's innovative approach not only aims to improve patient outcomes but also helps reduce costs in healthcare by enabling timely interventions.
Official SEC Documents
Advertisement